CA2865826A1 - Dosages de detection pour identifier et valider des agents qui ciblent des cellules souches cancereuses - Google Patents

Dosages de detection pour identifier et valider des agents qui ciblent des cellules souches cancereuses Download PDF

Info

Publication number
CA2865826A1
CA2865826A1 CA2865826A CA2865826A CA2865826A1 CA 2865826 A1 CA2865826 A1 CA 2865826A1 CA 2865826 A CA2865826 A CA 2865826A CA 2865826 A CA2865826 A CA 2865826A CA 2865826 A1 CA2865826 A1 CA 2865826A1
Authority
CA
Canada
Prior art keywords
stem cells
cells
cancer
cell
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2865826A
Other languages
English (en)
Inventor
Mickie Bhatia
Eleftherios Sachlos
Ruth Munoz Risueno
Tony Collins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McMaster University
Original Assignee
McMaster University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2012/000175 external-priority patent/WO2012116432A1/fr
Application filed by McMaster University filed Critical McMaster University
Priority to CA2865826A priority Critical patent/CA2865826A1/fr
Publication of CA2865826A1 publication Critical patent/CA2865826A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2865826A 2012-02-28 2013-02-28 Dosages de detection pour identifier et valider des agents qui ciblent des cellules souches cancereuses Abandoned CA2865826A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2865826A CA2865826A1 (fr) 2012-02-28 2013-02-28 Dosages de detection pour identifier et valider des agents qui ciblent des cellules souches cancereuses

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/CA2012/000175 WO2012116432A1 (fr) 2011-02-28 2012-02-28 Traitement du cancer par des antagonistes des récepteurs dopaminergiques
CAPCT/CA2012/000175 2012-02-28
US13/605,609 US9566282B2 (en) 2011-02-28 2012-09-06 Methods for identifying and validating selective anti-cancer stem cell agents
US13/605,609 2012-09-06
PCT/CA2013/000182 WO2013126993A1 (fr) 2011-02-28 2013-02-28 Dosages de détection pour identifier et valider des agents qui ciblent des cellules souches cancéreuses
CA2865826A CA2865826A1 (fr) 2012-02-28 2013-02-28 Dosages de detection pour identifier et valider des agents qui ciblent des cellules souches cancereuses

Publications (1)

Publication Number Publication Date
CA2865826A1 true CA2865826A1 (fr) 2013-09-06

Family

ID=51727196

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2865826A Abandoned CA2865826A1 (fr) 2012-02-28 2013-02-28 Dosages de detection pour identifier et valider des agents qui ciblent des cellules souches cancereuses

Country Status (1)

Country Link
CA (1) CA2865826A1 (fr)

Similar Documents

Publication Publication Date Title
EP2820148B1 (fr) Dosages de détection pour identifier et valider des agents qui ciblent des cellules souches cancéreuses
Sachlos et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells
US9486471B2 (en) Combination therapy for the treatment of cancer
Osman et al. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence
Noto et al. CD44 and SSEA-4 positive cells in an oral cancer cell line HSC-4 possess cancer stem-like cell characteristics
Marubayashi et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
Sampaio et al. Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review
Misaghian et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy
Scotlandi et al. Clinical relevance of Ki‐67 expression in bone tumors
Lang et al. A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia
AU2013203260B2 (en) Screening assays for identifying and validating agents that target cancer stem cells
Yao et al. Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm
Oki et al. Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML
Gotesman et al. mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL
Varotto et al. Diagnostic challenges in acute monoblastic/monocytic leukemia in children
Ammar et al. Overexpression of P‐glycoprotein and resistance to Imatinib in chronic myeloid leukemia patients
Kannan et al. Antileukemia effects of notch-mediated inhibition of oncogenic PLK1 in B-cell acute lymphoblastic leukemia
Rai et al. Clathrin assembly protein CALM plays a critical role in KIT signaling by regulating its cellular transport from early to late endosomes in hematopoietic cells
CA3148971A1 (fr) Procedes pour ameliorer la reponse d'un patient a des inhibiteurs du point de controle immunitaire et tests fonctionnels pour predire une reponse
CA2865826A1 (fr) Dosages de detection pour identifier et valider des agents qui ciblent des cellules souches cancereuses
Van Pham Breast Cancer Stem Cells & Therapy Resistance
SACHLOS et al. Patent 2868629 Summary
SACHLOS et al. Patent 2868629 Summary
Mayol et al. Characterisation of normal and cancer stem cells: one experimental paradigm for two kinds of stem cells
Verduin et al. Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140828

FZDE Discontinued

Effective date: 20190226